한국어
English
日本語
中文(简体)
Zavesca Capsule 100 mg (Miglustat)
100mg
Hard capsule · Prescription medication
(Co., Ltd.) Hanmi Pharmaceutical
Miglustat is an ingredient used to treat metabolic diseases by reducing the accumulation of glycosphingolipids.
MFDS ingredient code M246027
Miglustat is a drug that inhibits the synthesis of glucosylceramide, primarily used to reduce abnormal lipid accumulation in certain metabolic diseases. It is utilized in the treatment of rare genetic disorders and plays a role in regulating lipid metabolism in the body.
Miglustat decreases the accumulation of abnormal lipids in the body by inhibiting the production of a lipid called glucosylceramide. This improves cell function and alleviates the symptoms of metabolic diseases.
Approved uses differ by product. Check each product's information for its actual use.
Unlike other lipid regulators, miglustat acts at the synthesis stage of glucosylceramide, which allows for effective reduction of lipid accumulation in specific metabolic disorders.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.